277 related articles for article (PubMed ID: 17406000)
1. Promotion of bladder cancer development and progression by androgen receptor signals.
Miyamoto H; Yang Z; Chen YT; Ishiguro H; Uemura H; Kubota Y; Nagashima Y; Chang YJ; Hu YC; Tsai MY; Yeh S; Messing EM; Chang C
J Natl Cancer Inst; 2007 Apr; 99(7):558-68. PubMed ID: 17406000
[TBL] [Abstract][Full Text] [Related]
2. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
[TBL] [Abstract][Full Text] [Related]
3. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.
Mir C; Shariat SF; van der Kwast TH; Ashfaq R; Lotan Y; Evans A; Skeldon S; Hanna S; Vajpeyi R; Kuk C; Alkhateeb S; Morote J; van Rhijn BW; Bostrom P; Yao J; Miyamoto H; Jewett M; Fleshner N; Messing E; Zlotta AR
BJU Int; 2011 Jul; 108(1):24-30. PubMed ID: 21070579
[TBL] [Abstract][Full Text] [Related]
4. Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors.
Hata S; Ise K; Azmahani A; Konosu-Fukaya S; McNamara KM; Fujishima F; Shimada K; Mitsuzuka K; Arai Y; Sasano H; Nakamura Y
Life Sci; 2017 Dec; 190():15-20. PubMed ID: 28947209
[TBL] [Abstract][Full Text] [Related]
5. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy prevents bladder cancer recurrence.
Izumi K; Taguri M; Miyamoto H; Hara Y; Kishida T; Chiba K; Murai T; Hirai K; Suzuki K; Fujinami K; Ueki T; Udagawa K; Kitami K; Moriyama M; Miyoshi Y; Tsuchiya F; Ikeda I; Kobayashi K; Sato M; Morita S; Noguchi K; Uemura H
Oncotarget; 2014 Dec; 5(24):12665-74. PubMed ID: 25557268
[TBL] [Abstract][Full Text] [Related]
7. The role of the androgen receptor in the development and progression of bladder cancer.
Li Y; Izumi K; Miyamoto H
Jpn J Clin Oncol; 2012 Jul; 42(7):569-77. PubMed ID: 22593639
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of sex-hormone receptor expression in non-muscle-invasive bladder cancer.
Nam JK; Park SW; Lee SD; Chung MK
Yonsei Med J; 2014 Sep; 55(5):1214-21. PubMed ID: 25048477
[TBL] [Abstract][Full Text] [Related]
9. Implication of androgen receptor in urinary bladder cancer: a critical mini review.
Rahmani AH; Alzohairy M; Babiker AY; Khan AA; Aly SM; Rizvi MA
Int J Mol Epidemiol Genet; 2013; 4(3):150-5. PubMed ID: 24046807
[TBL] [Abstract][Full Text] [Related]
10. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
13. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
14. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition.
Jing Y; Cui D; Guo W; Jiang J; Jiang B; Lu Y; Zhao W; Wang X; Jiang Q; Han B; Xia S
Cancer Lett; 2014 Jun; 348(1-2):135-45. PubMed ID: 24662746
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.
Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G
Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492
[TBL] [Abstract][Full Text] [Related]
16. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.
Knowles MA; Hurst CD
Nat Rev Cancer; 2015 Jan; 15(1):25-41. PubMed ID: 25533674
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancers arise from distinct urothelial sub-populations.
Van Batavia J; Yamany T; Molotkov A; Dan H; Mansukhani M; Batourina E; Schneider K; Oyon D; Dunlop M; Wu XR; Cordon-Cardo C; Mendelsohn C
Nat Cell Biol; 2014 Oct; 16(10):982-91, 1-5. PubMed ID: 25218638
[TBL] [Abstract][Full Text] [Related]
18. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium.
Lin C; Yin Y; Stemler K; Humphrey P; Kibel AS; Mysorekar IU; Ma L
Cancer Res; 2013 Oct; 73(19):5914-25. PubMed ID: 23928991
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.
Chang C; Lee SO; Yeh S; Chang TM
Oncogene; 2014 Jun; 33(25):3225-34. PubMed ID: 23873027
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2.
Chen CC; Hsieh TF; Chang CH; Ma WL; Hung XF; Tsai YR; Lin MH; Zhang C; Chang C; Shyr CR
Oncol Rep; 2013 Aug; 30(2):979-85. PubMed ID: 23715826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
